Search

Your search keyword '"Faber, Edward A."' showing total 186 results
Start Over Author "Faber, Edward A."
Sorry, I don't understand your search. ×
186 results on '"Faber, Edward A."'

2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

3. Mind Matters 2: Engage and Develop Teams

Author

de Heer, Johan, Hrynkiewicz, Rafal, Faber, Edward, de Groot, Thomas, Oortwijn, Tije, Kacprzyk, Janusz, Series Editor, Pal, Nikhil R., Advisory Editor, Bello Perez, Rafael, Advisory Editor, Corchado, Emilio S., Advisory Editor, Hagras, Hani, Advisory Editor, Kóczy, László T., Advisory Editor, Kreinovich, Vladik, Advisory Editor, Lin, Chin-Teng, Advisory Editor, Lu, Jie, Advisory Editor, Melin, Patricia, Advisory Editor, Nedjah, Nadia, Advisory Editor, Nguyen, Ngoc Thanh, Advisory Editor, Wang, Jun, Advisory Editor, Kantola, Jussi Ilari, editor, and Nazir, Salman, editor

Published
2020
Full Text
View/download PDF

4. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Author

Laubach, Jacob, Moslehi, Javid, Francis, Sanjeev, San Miguel, Jesús, Sonneveld, Pieter, Orlowski, Robert, Moreau, Philippe, Rosiñol, Laura, Faber, Edward, Voorhees, Peter, Mateos, Maria-Victoria, Marquez, Loreta, Feng, Huaibao, Desai, Avinash, van de Velde, Helgi, Elliott, Jennifer, Shi, Hongliang, Dow, Edward, Jobanputra, Nishith, Esseltine, Dixie-Lee, Niculescu, Liviu, Anderson, Kenneth, Lonial, Sagar, and Richardson, Paul

Subjects
bortezomib, cardiac, cardio-oncology, multiple myeloma, Antineoplastic Agents, Benchmarking, Bortezomib, Cardiovascular Diseases, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Dyspnea, Heart Failure, Humans, Multiple Myeloma, Proteasome Inhibitors, Retrospective Studies, Risk Factors
Abstract

This retrospective analysis aimed to establish the overall cardiac safety profile of bortezomib using patient-level data from one phase 2 and seven phase 3 studies in previously untreated and relapsed/refractory multiple myeloma (MM). Seven clinically relevant primary [congestive heart failure (CHF), arrhythmias, ischaemic heart disease (IHD), cardiac death] and secondary (hypertension, dyspnoea, oedema) cardiac endpoints were defined based on MedDRA v16.0 preferred terms. 2509 bortezomib-treated patients and 1445 patients in non-bortezomib-based control arms were included. The incidence of grade ≥3 CHF was 1·3-4·0% in studies in relapsed/refractory MM and 1·2-4·7% in previously untreated MM (2·0-7·6% all grades), with no significant differences between bortezomib- and non-bortezomib-based arms in comparative studies. Incidences of arrhythmias (1·3-5·9% grade ≥2; 0·6-4·1% grade ≥3), IHD (1·2-2·9% all grades; 0·4-2·7% grade ≥3) and cardiac death (0-1·4%) were low, with no differences between bortezomib-based and non-bortezomib-based arms. Higher rates of oedema (mostly grade 1/2) were seen in bortezomib-based versus non-bortezomib-based arms in one study and a pooled transplant study analysis. Logistic regression analyses of comparative studies showed no impact on cardiac risk with bortezomib-based versus non-bortezomib-based treatment. Bortezomib-based treatment was associated with low incidences of cardiac events.

Published
2017

5. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Kumar, Shaji K, Jacobus, Susanna J, Cohen, Adam D, Weiss, Matthias, Callander, Natalie, Singh, Avina K, Parker, Terri L, Menter, Alexander, Yang, Xuezhong, Parsons, Benjamin, Kumar, Pankaj, Kapoor, Prashant, Rosenberg, Aaron, Zonder, Jeffrey A, Faber, Edward, Jr, Lonial, Sagar, Anderson, Kenneth C, Richardson, Paul G, Orlowski, Robert Z, Wagner, Lynne I, and Rajkumar, S Vincent

Published
2020
Full Text
View/download PDF

6. Mind Steering Leadership Game

Author

de Heer, Johan, Hrynkiewicz, Rafal, de Groot, Thomas, Faber, Edward, Kacprzyk, Janusz, Series editor, Pal, Nikhil R., Advisory editor, Bello Perez, Rafael, Advisory editor, Corchado, Emilio S., Advisory editor, Hagras, Hani, Advisory editor, Kóczy, László T., Advisory editor, Kreinovich, Vladik, Advisory editor, Lin, Chin-Teng, Advisory editor, Lu, Jie, Advisory editor, Melin, Patricia, Advisory editor, Nedjah, Nadia, Advisory editor, Nguyen, Ngoc Thanh, Advisory editor, Wang, Jun, Advisory editor, Kantola, Jussi Ilari, editor, Barath, Tibor, editor, and Nazir, Salman, editor

Published
2018
Full Text
View/download PDF

8. Curious Travellers

Author

Wilson, Andrew S., primary, Gaffney, Vince, additional, Gaffney, Chris, additional, Ch’ng, Eugene, additional, Bates, Richard, additional, Sears, Gareth, additional, Sparrow, Tom, additional, Murgatroyd, Andrew, additional, Faber, Edward, additional, and Coningham, Robin A.E., additional

Published
2019
Full Text
View/download PDF

12. Supplemental Table 3 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

13. Supplemental Table 2 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

14. Supplemental Figure Legend from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

15. Supplemental Figure from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

16. Supplemental Table 1 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., primary, Richardson, Paul G., primary, Schiller, Gary, primary, Hohl, Raymond J., primary, Cohen, Adam D., primary, Forero, Andres, primary, Carpenter, Susan, primary, Nguyen, Tuan S., primary, Conti, Ilaria, primary, Kaiser, Christopher J., primary, Cronier, Damien M., primary, Wooldridge, James E., primary, and Anderson, Kenneth C., primary

Published
2023
Full Text
View/download PDF

21. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Author

Yimer, Habte, primary, Melear, Jason, additional, Faber, Edward, additional, Bensinger, William I., additional, Burke, John M., additional, Narang, Mohit, additional, Stevens, Don, additional, Gray, Kathleen S., additional, Lutska, Yana, additional, Bobba, Padma, additional, Qi, Keqin, additional, Hoehn, Daniela, additional, Qi, Ming, additional, Lin, Thomas S., additional, and Rifkin, Robert M., additional

Published
2022
Full Text
View/download PDF

22. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma

Author

Hoda, Daanish, primary, Richards, Robert, additional, Faber, Edward A, additional, Deol, Abhinav, additional, Hunter, Bradley D, additional, Weber, Elizabeth, additional, DiFilippo, Heather, additional, Henderson-Clark, Toni, additional, Meaux, Linda, additional, Crivera, Concetta, additional, Riccobono, Carrie, additional, Garrett, Ashraf, additional, Jackson, Carolyn C, additional, Fowler, Jessica, additional, Theocharous, Panteli, additional, Stewart, Raj, additional, Lorden, Andrea L, additional, Porter, David L, additional, and Berger, Ariel, additional

Published
2022
Full Text
View/download PDF

26. Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Author

Hoda, Daanish, primary, Faber, Edward, additional, Hunter, Bradley, additional, Deol, Abhinav, additional, Crivera, Concetta, additional, Riccobono, Carrie, additional, Garrett, Ashraf, additional, Jackson, Carolyn C., additional, Fowler, Jessica, additional, Berger, Ariel, additional, Lorden, Andrea L, additional, and Stewart, Raj, additional

Published
2021
Full Text
View/download PDF

27. Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.

Author

Rifkin, Robert M., primary, Melear, Jason M., additional, Faber, Edward, additional, Bensinger, William I., additional, Burke, John M., additional, Narang, Mohit, additional, Stevens, Don A., additional, Gray, Kathleen, additional, Lutska, Yana, additional, Bobba, Padma, additional, Qi, Keqin, additional, Qi, Ming, additional, Lin, Thomas S., additional, and Yimer, Habte Aragaw, additional

Published
2021
Full Text
View/download PDF

28. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (E1A11): a multicenter, open label, phase 3, randomized, controlled trial

Author

Kumar, Shaji K., Jacobus, Susanna J., Cohen, Adam D., Weiss, Matthias, Callander, Natalie Scott, Singh, Avina K., Parker, Terri L., Menter, Alexander, Yang, Xuezhong, Parsons, Benjamin Marshall, Kumar, Pankaj, Kapoor, Prashant, Rosenberg, Aaron Seth, Zonder, Jeffrey A., Faber, Edward Anthony, Lonial, Sagar, Anderson, Kenneth C., Richardson, Paul G., Orlowski, Robert Z., Wagner, Lynne I., and Rajkumar, S. Vincent

Subjects
Article
Abstract

SUMMARY: BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma (NDMM). Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide, and dexamethasone (KRd) has shown excellent efficacy in phase II trials and may improve outcomes compared with VRd. METHODS: In this randomized, open label, phase 3 trial, we recruited patients with NDMM, aged 18 years and older, who were not planned for immediate autologous stem-cell transplant (ASCT). Key inclusion was absence of the following high-risk features (del17p, t(14;16), t(14;20), plasma cell leukemia) and Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Patients were randomized (1:1) to receive VRd or KRd for 36 weeks followed by a 2(nd) randomization (1:1) to indefinite versus 2 years of lenalidomide maintenance. Allocation was stratified by intent to ASCT at disease progression and was not masked to investigators and patients. VRd regimen included bortezomib 1·3 mg/m(2) on days 1, 4, 8, and 11 (d 1, 8 for cycles 9–12), lenalidomide 25 mg daily on days 1–14, and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 for twelve 3-week cycles. KRd regimen included carfilzomib 36 mg/m(2) on days 1, 2, 8, 9, 15, 16, lenalidomide 25 mg daily on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22 for nine 4-week cycles. The primary endpoint was progression-free survival, defined as the time from first randomization to disease progression or death, analyzed by intention to treat. Safety was assessed in patients who received at least one dose of their assigned treatment. Study recruitment is complete, all patients have completed induction therapy, and patients continue on maintenance as per second randomization and follow up is ongoing. The trial is registered at ClinicalTrials.gov:NCT01863550. FINDINGS: Between December 6, 2013 and February 6, 2019, we randomly assigned 1087 patients at 272 participating institutions (542 to VRd, 545 to KRd). At an estimated median (IQR) follow-up of 9 (5–23) months from randomization, median PFS was 34·4 (95% CI 30·1-NE) months for VRd compared with 34·6 (95% CI 28·8–37·8) months for KRd; the PFS treatment hazard ratio (HR=KRd/VRd) was 1·04 (95% CI 0·83–1·31); P=0·74. The most common grade 3–4 non-hematologic adverse events included fatigue (34 [6%] vs. 29 [6%]), hyperglycemia (23 [4%] vs. 34[7%]), peripheral neuropathy (44 [8%]vs. 4 [

Published
2020

32. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Author

Kumar, Shaji, primary, Jacobus, Susanna J., additional, Cohen, Adam D., additional, Weiss, Matthias, additional, Callander, Natalie Scott, additional, Singh, Avina A., additional, Parker, Terri L., additional, Menter, Alex R., additional, Yang, Xuezhong, additional, Parsons, Benjamin Marshall, additional, Kumar, Pankaj, additional, Kapoor, Prashant, additional, Rosenberg, Aaron Seth, additional, Zonder, Jeffrey A., additional, Faber, Edward Anthony, additional, Lonial, Sagar, additional, Richardson, Paul G., additional, Orlowski, Robert Z., additional, Wagner, Lynne I., additional, and Rajkumar, S. Vincent, additional

Published
2020
Full Text
View/download PDF

33. Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Author

Rifkin, Robert M., primary, Melear, Jason M., primary, Faber, Edward, primary, Bensinger, William I., primary, Burke, John M, primary, Narang, Mohit, primary, Stevens, Don, primary, Gunawardena, Sriya, primary, Lutska, Yana, primary, Qi, Keqin, primary, Ukropec, Jon, primary, Qi, Ming, primary, Lin, Thomas S., primary, and Yimer, Habte A, primary

Published
2019
Full Text
View/download PDF

34. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma:LYRAstudy

Author

Yimer, Habte, primary, Melear, Jason, additional, Faber, Edward, additional, Bensinger, William I., additional, Burke, John M., additional, Narang, Mohit, additional, Stevens, Don, additional, Gunawardena, Sriya, additional, Lutska, Yana, additional, Qi, Keqin, additional, Ukropec, Jon, additional, Qi, Ming, additional, Lin, Thomas S., additional, and Rifkin, Robert M., additional

Published
2019
Full Text
View/download PDF

36. Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Author

Yimer, Habte, primary, Melear, Jason, additional, Faber, Edward, additional, Bensinger, William, additional, Burke, John M, additional, Narang, Mohit, additional, Stevens, Don, additional, Gunawardena, Sriya W., additional, Lutska, Yana, additional, Qi, Keqin, additional, Ukropec, Jon, additional, Qi, Ming, additional, Lin, Thomas, additional, and Rifkin, Robert M, additional

Published
2018
Full Text
View/download PDF

37. Balancing customer and network value in business models for mobile services

Author

Haaker, Timber, Faber, Edward, and Bouwman, Harry

Subjects
Business -- Models, Business -- Analysis, Telecommunications industry
Abstract

Byline: Timber Haaker, Edward Faber, Harry Bouwman Designing business models for mobile services is complex. A business model can be seen as a blueprint of four interrelated components: service offering, technical architecture, and organisational and financial arrangements. In this paper the connections among these components are explored by analysing the critical design issues in business models for mobile services, e.g., targeting and branding in the service domain, security and quality of service in the technology domain, network governance in the organisation domain, and revenue sharing in the finance domain. A causal framework is developed linking these critical design issues to expected customer value and expected network value, and hence, to business model viability.

Published
2006

40. Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Author

Raje, Noopur S., primary, Faber, Edward A., additional, Richardson, Paul G., additional, Schiller, Gary, additional, Hohl, Raymond J., additional, Cohen, Adam D., additional, Forero, Andres, additional, Carpenter, Susan, additional, Nguyen, Tuan S., additional, Conti, Ilaria, additional, Kaiser, Christopher J., additional, Cronier, Damien M., additional, Wooldridge, James E., additional, and Anderson, Kenneth C., additional

Published
2016
Full Text
View/download PDF

41. Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Author

Zonder, Jeffrey A, primary, Usmani, Saad, additional, Scott, Emma C., additional, Hofmeister, Craig C., additional, Lendvai, Nikoletta, additional, Berdeja, Jesus G., additional, Anderson, Larry D., additional, Hari, Parameswaran, additional, Singhal, Seema, additional, Orloff, Gregory, additional, Craig, Michael, additional, Valent, Jason, additional, Lee, Wes, additional, Hart, Lowell, additional, Hrom, J, additional, Tarantolo, Stephano, additional, Faber, Edward, additional, Schiller, Gary J, additional, Schreiber, Jennifer, additional, Oliver, Colleen, additional, Rush, Selena A, additional, Tunquist, Brian, additional, Ptaszynski, Mieke, additional, and Raje, Noopur S., additional

Published
2015
Full Text
View/download PDF

42. A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts

Author

Berdeja, Jesus G., primary, Gregory, Tara B., additional, Faber, Edward A., additional, Matous, Jeffrey V., additional, Hart, Lowell L., additional, Mace, Joseph R., additional, Peyton, James D., additional, Essell, James H., additional, Arrowsmith, Edward R., additional, and Flinn, Ian W., additional

Published
2015
Full Text
View/download PDF

44. Security applications for converging technologies : impact on the constitutional state and the legal order

Author

Teeuw, Wouter B., Vedder, Anton H., Custers, Bart H.M., Dorbeck-Jung, Barbel R., Faber, Edward C.C., Iacob, Sorin M., Koops, Bert-Jaap, Leenes, Ronald E., de Poot, Henk J.G., Rip, Arie, Vudisa, Jacques N., and Faculty of Behavioural, Management and Social Sciences

Subjects
METIS-253298, IR-102136
Abstract

The impact of converging technologies on legal practice and criminology is being investigated in a forward looking study intended for practitioners and policy makers in the field of legislation, crime prevention, and law enforcement. This report consists of three parts. The first part describes the state of the art and future expectations on nano-, bio-, ICT and cognitive science and technology, as well as their convergence. The second part describes the (future) applicability of converging technologies to our application domain, in particular in three cases. This part ends with scenarios that are used as a means to ‘visualize’ the developments and an input for the impact analysis. In the third part the scenarios are analysed on their ethical, legal and social implications. This part describes the major social and normative trends that are observed.

Published
2008

45. Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Author

Yimer, Habte, Melear, Jason, Faber, Edward, Bensinger, William I., Burke, John M, Gunawardena, Sriya, Sean, Murphy, Parros, Hollee, Lutska, Yana, Darif, Mohamed, Londhe, Anil, Qi, Ming, Ukropec, Jon, Lin, Thomas, and Rifkin, Robert M.

Published
2017
Full Text
View/download PDF

46. Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Author

Wood, William A., primary, Le-Rademacher, Jennifer, additional, Fei, Mingwei, additional, Logan, Brent R., additional, Syrjala, Karen L, additional, Majhail, Navneet S., additional, Wingard, John R., additional, Abidi, Muneer H., additional, Geller, Nancy L., additional, Wu, Juan, additional, Rizzo, J. Douglas, additional, Faber, Edward A, additional, Jim, Heather, additional, Jacobsen, Paul, additional, Horowitz, Mary M., additional, and Lee, Stephanie J., additional

Published
2014
Full Text
View/download PDF

47. Towards a comprehensive framework to analyse edutainment applications.

Author

Santonen, Teemu and Faber, Edward

Subjects
EDUCATIONAL entertainment, EDUCATIONAL technology, DIGITAL technology, VIDEO games, LEARNING
Abstract

By following action research principles this study develops a comprehensive framework that enables more systematical data collection on the design and impact of edutainment applications, in particular serious games and gamification, from learning and learner's points of view. Schell's original game design framework including aesthetics, story, mechanics and technology dimensions was enhanced with pedagogy and player dimensions. Moreover, these abstract dimensions were decomposed into individual functional elements on the basis of prior findings in literature. The enhanced framework was tested with four serious games. The framework helped to gain deeper insight in design choices being made and reveals subtle differences between game designs. There is, however, room for improvement. Some elements seem to be partly overlapping; others do not seem to differentiate much across different games. More research is needed to fine-tune and operationalize the framework elements. [ABSTRACT FROM AUTHOR]

Published
2015

48. Serious Gaming for Change in Air Traffic Management.

Author

Faber, Edward, Aalmoes, Roalt, de Groot, Thomas, Hrynkiewicz, Rafal, and Nieuwenhuisen, Dennis

Subjects
AIR traffic control, TECHNOLOGICAL innovations, ORGANIZATIONAL change, VIDEO games, STAKEHOLDERS, MANAGEMENT
Abstract

Introducing change in Air Traffic Management (ATM) is a complex activity requiring the collaboration of multiple stakeholders. We report on an action research study, which explores how stakeholders can be made aware of the characteristics of ATM innovations using a serious game. The findings provide first - not conclusive - empirical support that games can help make people aware of characteristics, costs and benefits of new technological concepts. Also, support is found that gaming helps to create a more collaborative climate among stakeholders in the introduction of new technologies. As such, serious games have the potential to become a serious tool to facilitate change processes. This research contributes to our understanding of serious gaming for change in two ways. First, it shows how serious games can be used to support change processes. Second, it provides insights how stakeholders can be made aware of introducing technological innovations using a serious game. [ABSTRACT FROM AUTHOR]

Published
2015

50. Inter-organisational project management in context: managing differences

Author

Wognum, P.M. (Nel), Faber, Edward C.C., Thoben, K.D., Weber, F., Pawar, K.S., and Faculty of Behavioural, Management and Social Sciences

Subjects
Product and process development, Inter-organisational collaboration, Project management
Abstract

Although in many organisations projects are run according to a standard procedure many projects run out of time and budget, don't achieve the required quality standards, or don't even finish at all. This is especially the case for large and complex projects with large differences between the parties involved. Although there is much knowledge and experience on what the causes are of sub-optimal project performance, this knowledge is still rather experential and anecdotal. In this paper, we will present a systematic approach towards building knowledge on factors influencing multi-site project behaviour. For this purpose, we will consider projects as temporary organisations. We will identify three classes of problems, which may lead to project failure. The paper addresses part of the causes of problems, namely differences between project parties. Our research focuses on new product development projects performed at multiple sites. A model will be presented of essential classes of differences to take into account in managing a project. In addition, a learning approach towards supporting project management in identifying and managing differences will be presented. The approach is illustrated with examples from a longitudinal case study into Dutch-Mexican collaborative projects.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results